A phase 1 study of CB-011, a CRISPR-edited allogeneic CAR-T targeting BCMA, in patients with multiple myeloma

In February 2021, LLS made an equity investment in Caribou Biosciences to support "A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma." CB-011 is the first allogeneic anti-BCMA CAR-T cell therapy that is engineered to improve persistence of antitumor response through an immune cloaking genome-editing approach to prevent both T- and NK-mediated immune rejection. Caribou's immune cloaking strategy is expected to drive CAR-T cell persistence, enabling more durable antitumor activity. CB-011 is being evaluated in the ongoing, open-label, multicenter Phase 1 CaMMouflage clinical trial in the United States in adults with relapsed or refractory multiple myeloma.